» Articles » PMID: 37373389

Proteolytic Resistance Determines Albumin Nanoparticle Drug Delivery Properties and Increases Cathepsin B, D, and G Expression

Abstract

Proteolytic activity is pivotal in maintaining cell homeostasis and function. In pathological conditions such as cancer, it covers a key role in tumor cell viability, spreading to distant organs, and response to the treatment. Endosomes represent one of the major sites of cellular proteolytic activity and very often represent the final destination of internalized nanoformulations. However, little information about nanoparticle impact on the biology of these organelles is available even though they represent the major location of drug release. In this work, we generated albumin nanoparticles with a different resistance to proteolysis by finely tuning the amount of cross-linker used to stabilize the carriers. After careful characterization of the particles and measurement of their degradation in proteolytic conditions, we determined a relationship between their sensitivity to proteases and their drug delivery properties. These phenomena were characterized by an overall increase in the expression of cathepsin proteases regardless of the different sensitivity of the particles to proteolytic degradation.

Citing Articles

Biologics-based technologies for highly efficient and targeted RNA delivery.

Kostyusheva A, Brezgin S, Ponomareva N, Frolova A, Lunin A, Bayurova E Mol Ther. 2024; 33(1):168-183.

PMID: 39511888 PMC: 11764554. DOI: 10.1016/j.ymthe.2024.11.004.


Physiologically based pharmacokinetic model for predicting the biodistribution of albumin nanoparticles after induction and recovery from acute lung injury.

Kutumova E, Akberdin I, Egorova V, Kolesova E, Parodi A, Pokrovsky V Heliyon. 2024; 10(10):e30962.

PMID: 38803942 PMC: 11128879. DOI: 10.1016/j.heliyon.2024.e30962.


The Intricate Balance between Life and Death: ROS, Cathepsins, and Their Interplay in Cell Death and Autophagy.

Voronina M, Frolova A, Kolesova E, Kuldyushev N, Parodi A, Zamyatnin Jr A Int J Mol Sci. 2024; 25(7).

PMID: 38612897 PMC: 11012956. DOI: 10.3390/ijms25074087.


Smart Delivery Systems Responsive to Cathepsin B Activity for Cancer Treatment.

Egorova V, Kolesova E, Lopus M, Yan N, Parodi A, Zamyatnin Jr A Pharmaceutics. 2023; 15(7).

PMID: 37514035 PMC: 10386206. DOI: 10.3390/pharmaceutics15071848.

References
1.
Ballabio A, Bonifacino J . Lysosomes as dynamic regulators of cell and organismal homeostasis. Nat Rev Mol Cell Biol. 2019; 21(2):101-118. DOI: 10.1038/s41580-019-0185-4. View

2.
Di Spiezio A, Marques A, Schmidt L, Thiessen N, Gallwitz L, Fogh J . Analysis of cathepsin B and cathepsin L treatment to clear toxic lysosomal protein aggregates in neuronal ceroid lipofuscinosis. Biochim Biophys Acta Mol Basis Dis. 2021; 1867(10):166205. DOI: 10.1016/j.bbadis.2021.166205. View

3.
Zhang C, Zhang M, Song S . Cathepsin D enhances breast cancer invasion and metastasis through promoting hepsin ubiquitin-proteasome degradation. Cancer Lett. 2018; 438:105-115. DOI: 10.1016/j.canlet.2018.09.021. View

4.
Busatto C, Pesoa J, Helbling I, Luna J, Estenoz D . Effect of particle size, polydispersity and polymer degradation on progesterone release from PLGA microparticles: Experimental and mathematical modeling. Int J Pharm. 2017; 536(1):360-369. DOI: 10.1016/j.ijpharm.2017.12.006. View

5.
Wang T, Xue J, Hu Q, Zhou M, Chang C, Luo Y . Synthetic surfactant- and cross-linker-free preparation of highly stable lipid-polymer hybrid nanoparticles as potential oral delivery vehicles. Sci Rep. 2017; 7(1):2750. PMC: 5459848. DOI: 10.1038/s41598-017-02867-x. View